uniQure N.V. (NASDAQ:QURE) – Equities research analysts at Leerink Swann issued their FY2019 earnings per share estimates for shares of uniQure N.V. in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz anticipates that the biotechnology company will post earnings of ($1.95) per share for the year. Leerink Swann also issued estimates for uniQure N.V.’s FY2020 earnings at ($2.05) EPS.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of uniQure N.V. from a “sell” rating to a “hold” rating in a report on Wednesday. Oppenheimer Holdings, Inc. set a $17.00 price target on shares of uniQure N.V. and gave the company a “buy” rating in a report on Tuesday, May 16th. ValuEngine downgraded shares of uniQure N.V. from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “hold” rating and set a $8.00 price target on shares of uniQure N.V. in a report on Wednesday, April 12th. Finally, Cowen and Company reissued a “buy” rating on shares of uniQure N.V. in a report on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $14.61.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Expectations for uniQure N.V.’s FY2019 Earnings (QURE)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2798055/analysts-set-expectations-for-uniqure-n-v-s-fy2019-earnings-qure.html.
uniQure N.V. (NASDAQ:QURE) traded down 4.27% during mid-day trading on Thursday, reaching $8.30. 61,849 shares of the company traded hands. The stock’s market capitalization is $212.15 million. The firm’s 50-day moving average is $7.15 and its 200 day moving average is $6.04. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $9.72.
uniQure N.V. (NASDAQ:QURE) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative net margin of 203.99% and a negative return on equity of 116.61%. The company had revenue of $4.94 million during the quarter, compared to analyst estimates of $2.92 million.
In related news, insider Harald Petry sold 49,300 shares of uniQure N.V. stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $6.02, for a total transaction of $296,786.00. Following the sale, the insider now directly owns 27,753 shares in the company, valued at $167,073.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 173,460 shares of company stock worth $1,042,986. Company insiders own 0.64% of the company’s stock.
Several large investors have recently modified their holdings of QURE. JPMorgan Chase & Co. boosted its stake in shares of uniQure N.V. by 33.5% in the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after buying an additional 14,659 shares in the last quarter. Paloma Partners Management Co boosted its stake in shares of uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after buying an additional 74,605 shares in the last quarter. Weiss Multi Strategy Advisers LLC boosted its stake in shares of uniQure N.V. by 266.7% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock worth $318,000 after buying an additional 40,000 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after buying an additional 122,700 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of uniQure N.V. by 14.9% in the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after buying an additional 73,418 shares in the last quarter. Institutional investors and hedge funds own 30.22% of the company’s stock.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.